FDA Approval Of Tessie Puts Orion’s Animal Health Potential In Focus

• Orion Oyj (HLSE:ORNBV) has received FDA approval for its proprietary veterinary drug Tessie (tasipimidine) for use in the U.S. market.
• Tessie is approved as a treatment option for noise aversion and separation anxiety in dogs.
• The product will be commercialized in the United States through Orion’s partner Zoetis.

For Orion, known for its human pharmaceuticals and animal health products, Tessie adds a new proprietary molecule to its pet care offering at a time when spending on companion animals continues to attract attention from global drug companies. The FDA approval confirms that Tessie meets U.S. regulatory standards for safety and efficacy in its indicated use, which can matter for how veterinarians and pet owners view the product.

As Zoetis introduces Tessie to U.S. veterinarians and clinics, investors watching HLSE:ORNBV may focus on how Orion builds awareness in this segment and how this development relates to its broader animal health portfolio. The approval may also influence how Orion approaches future product development and potential partnerships in other markets and therapeutic areas within animal health.

Stay updated on the most important news stories for Orion Oyj by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on Orion Oyj.

📰 Beyond the headline: 1 risk and 3 things going right for Orion Oyj that every investor should see.

Tessie broadens Orion’s animal health offering with a proprietary central-nervous-system drug targeting noise aversion and separation anxiety in dogs, an area where pet owners often seek long-term treatment options. For investors, the key angle is that tasipimidine is Orion’s own molecule and a new active substance for veterinary use in the U.S., which can support pricing power and product differentiation. Commercialization through Zoetis places Tessie in the same portfolio as Sileo and Bonqat, giving it exposure to an established U.S. distribution network in companion-animal behavior. Competitors in animal health such as Elanco and Boehringer Ingelheim also target companion animals, so performance over time will depend on how Tessie is positioned against alternative therapies and how veterinarians adopt it alongside existing products.

How This Fits Into The Orion Oyj Narrative

• This approval adds another proprietary product alongside oncology and base-business growth, supporting the narrative that Orion can build multiple earnings streams across human and animal health.
• Analyst focus on oncology and human medicines could be challenged if Tessie and other animal health products take a larger role in Orion’s earnings mix than previously expected.
• The narrative highlights broad animal health exposure but does not fully reflect the specific opportunity in behavioral disorders in dogs or the commercial impact of Zoetis having exclusive U.S. rights.

Knowing what a company is worth starts with understanding its story.
Check out one of the top narratives in the Simply Wall St Community for Orion Oyj to help decide what it’s worth to you.

The Risks and Rewards Investors Should Consider

• Uptake for Tessie depends on veterinarian and pet-owner acceptance of a new central-nervous-system drug in a category where non-drug approaches and existing products already compete for attention.
• Analysts have flagged 1 major risk related to the quality of earnings, so investors may want to watch how Tessie contributes to cash-generating profits versus non cash items over time.
• Tessie leverages Zoetis’ established U.S. reach in companion-animal behavior products, which can help Orion access a wide customer base without building its own commercial infrastructure in the market.
• Adding a proprietary veterinary molecule can support Orion’s broader animal health positioning as the company continues to grow across divisions like Innovative Medicines, Generics and Branded Products.

What To Watch Going Forward

From here, investors may want to follow the timing of Tessie’s U.S. launch, pricing and label positioning relative to Sileo and Bonqat in Zoetis’ behavioral portfolio. Over time, Orion’s disclosures on animal health sales and any commentary on Tessie’s contribution to that segment will be important signals. It is also worth tracking whether Orion seeks approvals for tasipimidine in additional markets or indications, as that would shape the long-term role of animal health within its overall business mix.

To ensure you’re always in the loop on how the latest news impacts the investment narrative for Orion Oyj, head to the
community page for Orion Oyj to never miss an update on the top community narratives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com